IL1B and neoplasm: These results indicate that treatment with engineered Salmonella expressing lux/pT-ClyA results in significant suppression of tumor growth, and IL-1β production by S.t-ΔpGlux/pT-ClyA increases therapeutic efficacy (Fig. 3a, b).